Vaderis Therapeutics Secures Major Series B Funding
Vaderis Therapeutics, a company focused on developing innovative treatments for cardiovascular diseases, has successfully raised $152 million in a Series B funding round. This significant financial boost will aid the Basel, Switzerland-based biotech firm in its ongoing efforts to advance its therapeutic pipeline.
Investment Details
The Series B round was led by Life Sciences at Goldman Sachs Alternatives and TCGX. Other prominent investors included Omega Funds, EQT Life Sciences, Perceptive Advisors, Kalehua Capital, Medicxi, and Droia. This diverse group of investors reflects strong confidence in Vaderis Therapeutics' potential to impact the cardiovascular treatment landscape.
Leadership and Vision
Under the leadership of President and CEO Azmi Nabulsi, Vaderis Therapeutics is committed to addressing unmet needs in cardiovascular care. Co-Founders Pierre Saint-Mezard, who also serves as the Chief Scientific Officer, and Damien Picard have been instrumental in driving the company’s scientific and strategic direction.
Use of Funds
While the specific allocation of the $152 million was not disclosed, it is expected that the funds will support the advancement of clinical trials, further development of the company’s drug pipeline, and potential expansion into new markets.
Company Overview
Vaderis Therapeutics continues to position itself as a key player in the biotech industry, with a focus on pioneering therapies that address significant gaps in cardiovascular disease treatment. As the company moves forward with its latest round of funding, stakeholders and patients alike will be watching closely for the next stages of its development.